Popular Articles
Stretch Mark Cream

Study Results Present Efficacy And Safety Findings From The PHIRST-1 Study Of Patients With Pulmonary Arterial Hypertension
United Therapeutics Corporation (Nasdaq: UTHR) and Eli Lilly and Company (NYSE: LLY) today announced the results of a pivotal 16-week study showing that a once-daily dose of tadalafil was generally well tolerated, improved exercise capacity and improved time to clinical worsening in patients with pulmonary arterial hypertension (PAH)(1). The randomized, double-blind, 16-week, placebo-controlled Phase 3 study followed 405 patients with PAH, either treatment-naive or taking bosentan, randomized to placebo or tadalafil 2.5 mg, 10 mg, 20 mg or 40 mg orally. Results from the study entitled, "Tadalafil Therapy for Pulmonary Arterial Hypertension," were published in today"s issue of Circulation.
generic viagra online
Health Reform Stalled In Congress By Busy Schedule, Divided Lawmakers
"Lawmakers from both parties are telling the White House they will go on vacation next month and leave behind - and incomplete - President Barack Obama"s health care overhaul," the Associated Press reports. The White House had long pushed lawmakers to complete their proposal by the recess, a target that now appears unlikely. Purchase zoloft to treat depression.
News of the day
Synchronized Swimming Of Algae May Have Significant Implications For Human Health And Disease
Using high-speed cinematography, scientists at Cambridge University have discovered that individual algal cells can regulate the beating of their flagella in and out of synchrony in a manner that controls their swimming trajectories. Their research was published on the 24th July in the journal Science.
Health Insurance

WHO Approves HPV Vaccine Cervarix For Use In Developing Countries

The World Health Organization has approved GlaxoSmithKline"s human papillomavirus vaccine Cervarix, thus enabling United Nations agencies and partners to officially purchase millions of doses for use in low-income nations, the AP/San Diego Union-Tribune reports (AP/San Diego Union-Tribune, 7/9). Cervarix is highly effective at preventing HPV types 16 and 18, which cause about 70% of cervical cancer cases (GSK release, 7/9). According to the AP/Union-Tribune, more than 80% of the estimated 280,000 cervical cancer deaths annually occur in developing countries.Cervarix has not been approved for use in the U.S. and Japan, but it is available in 97 other countries. FDA is expected to decide in the next few months whether to approve Cervarix for use in the U.S. (AP/San Diego Union-Tribune, 7/9). The agency in 2006 approved Merck"s HPV vaccine Gardasil for girls and women ages nine to 26. Centers for Disease Control and Prevention guidelines recommend routine three-dose vaccination for girls ages 11 and 12 and for girls and women ages 13 to 26 who have not yet been vaccinated (CDC fact sheet, June 2008).The three-shot regimen typically costs about $360. It is unclear if GSK will provide Cervarix at a lower cost to U.N. agencies purchasing it for developing countries (AP/San Diego Union-Tribune, 7/9). GSK said that it is "eager to work with our long-term partner GAVI as well as other private [non-governmental organizations] or governments of developing countries to identify financing mechanisms for the vaccine" (Stovall, Dow Jones, 7/9). The global health association GAVI is a major buyer of vaccines for the developing world. In 2008, GAVI prioritized the purchase of HPV vaccines for the world"s 73 poorest nations. The organization includes U.N. agencies, the World Bank and the Bill and Melinda Gates Foundation (AP/San Diego Union-Tribune, 7/9). Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women"s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women"s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company. © 2009 The Advisory Board Company. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):